1. 1) El-Serag HB. 2012. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142: 1264-1273.
2. 2) Zeng H, Zheng R, Guo Y, Zhang S, Zou X, Wang N, Zhang L, Tang J, Chen J, Wei K, Huang S, Wang J, Yu L, Zhao D, Song G, Chen J, Shen Y, Yang X, Gu X, Jin F, Li Q, Li Y, Ge H, Zhu F, Dong J, Guo G, Wu M, Du L, Sun X, He Y, Coleman MP, Baade P, Chen W, Yu XQ. 2014. Cancer survival in China, 2003-2005: A population-based study. Int J Cancer 136: 1921-1930.
3. 3) Steward WP, Brown K. 2013. Cancer chemoprevention: a rapidly evolving field. Br J Cancer 109: 1-7.
4. 4) Kakizoe T. 2003. Chemoprevention of cancer—focusing on clinical trials. Jpn J Clin Oncol 33: 421-442.
5. 5) Okita K, Izumi N, Ikeda K, Osaki Y, Numata K, Ikeda M, Kokudo N, Imanaka K, Nishiguchi S, Kondo S, Nishigaki Y, Shiomi S, Ueshima K, Isoda N, Karino Y, Kudo M, Tanaka K, Kaneko S, Moriwaki H, Makuuchi M, Okusaka T, Hayashi N, Ohashi Y, Kumada H; The Peretinoin Study Group. 2014. Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial. J Gastroenterol 50: 667-674.